Diagnosis and management of depression in primary care: A clinical update and review

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 11, 2002, Pages 1253-1260

  Remick, Ronald A ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LIOTHYRONINE SODIUM; LITHIUM; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DEPRESSION; DIAGNOSTIC PROCEDURE; DRUG CHOICE; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERICUM PERFORATUM; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT EDUCATION; PHOTOTHERAPY; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; REVIEW; SUICIDAL BEHAVIOR;

EID: 0036435077     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Murphy JM, Laird NM, Monson RR, Sobel AM, Leighton AH. A 40-year perspective on the prevalence of depression: The Stirling County Study. Arch Gen Psychiatry 2000;57:209-15.
2. Duffy A. Towards effective early intervention and prevention strategies for major affective disorders: A review of antecedents and risk factors. Can J Psychiatry 2000;45:340-8.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington: The Association; 1994.
4. Bland RC. Epidemiology of affective disorders: A review. Can J Psychiatry 1997;42(4):367-77.
5. Sadovnick AD, Remick RA, Lam RW, Zis AP, Yee IM, Huggins NJ, et al. Mood Disorder Service Genetic Database: Morbidity risks for mood disorders in 3,942 first-degree relatives of 671 index cases with single depression, recurrent depression, bipolar I, or bipolar II. Am J Med Genet 1994;54:132-40.
6. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
7. Enns MW, Swenson JR, McIntyre RS, Swinson RP, Kennedy SH, and the CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry 2001;46(Suppl 1):77S-90S.
8. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-9.
9. Patten SB. Incidence of major depression in Canada. CMAJ 2000;163:714-5.
10. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: A re-examination. Am J Psychiatry 2000;157:1925-32.
11. Sakinofsky I, Leenaars AA. Suicide in Canada with special reference to the difference between Canada and the United States. Suicide Life Threat Behav 1997;27:112-26.
12. Parikh SV, Wasylenki D, Goerung P, Wong J. Mood disorders: Rural/urban differences in prevalence, health care utilization, and disability in Ontario. J Affect Disord 1996;38:57-65.
13. Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, et al. Depression in the workplace: Effects on short-term disability. Health Aff (Millwood) 1999;18:163-71.
14. Denihan A, Bruce I, Coakley D, Lawlor BA. Psychiatry morbidity in cohabitants of community-dwelling elderly depressives. Int J Geriatr Psychiatry 1998;13:691-4.
15. Goodman SH, Gotlib IH. Risk for psychopathology in the children of depressed mothers: A developmental model for understanding mechanisms of transmission. Psychol Rev 1999;106:458-90.
16. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997;349:1498-504.
17. Gredon JF. The burden of disease in treatment-resistant depression. J Clin Psychiatry 2001;62:26-31.
18. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18 month prognosis after myocardial infarction. Circulation 1995;91:999-1005.
19. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123-9.
20. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001;88:337-41.
21. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease. Arch Gen Psychiatry 1998;55:580-92.
22. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-608.
23. Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder. New York: Cambridge University Press; 2000. p. 20-63.
24. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000;5:578-93.
25. Drevets WC. Functioning neuroimaging studies of depression: The anatomy of melancholia. Annu Rev Med 1998;49:341-61.
26. Vaidya VA, Sivciak JA, Du F, Dumnan RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 1999;89:157-66.
27. Thase ME. Neuroimaging profiles and the differential therapies of depression. Arch Gen Psychiatry 2001;58:651-2.
28. Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci 2001;26(Suppl):S3-10.
29. Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996;153:1411-7.
30. Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Friedman SJ, Meyers BS. Stigma as a barrier to recovery. Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv 2001; 52:1615-20.
31. Nemeroff CB, Compton MT, Berger J. The depressed suicidal patient. Assessment and treatment. Ann N Y Acad Sci 2001;932:1-23.
32. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: A meta-analysis. Can J Psychiatry 1996;41:613-6.
33. Moller HJ, Fuger J, Kasper S. Efficacy of new generation antidepressant: Meta-analysis of imipramine-controlled studies. Pharmacopsychiatry 1994;27:215-23.
34. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-4.
35. Kennedy SH, Lam RW, Cohen NL, Ravindran AV, and the CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38S-58S.
36. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(4 Suppl):1-45.
37. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressents: A meta-analysis. CMAJ 1998;159(10):1245-52.
38. Jefferson JW. Drug interactions - Friend or foe? J Clin Psychiatry 1998;59 (Suppl 4):37-47.
39. Nierenberg AA, McLean NE, Alpert JG, Worthington JJ, Rosenbaum JF, Fava M. Early non-response to fluoxetine as a predictor of poor 8 week outcome. Am J Psychiatry 1995;152:1500-3.
40. Bauer M, Dopfiner S. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19:427-34.
41. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-22.
42. Warneke L. Psychostimulants in psychiatry. Can J Psychiatry 1990;35:3-10.
43. Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L. Pharmacological and psychological treatments for depressed older patients: A meta-analysis and overview of recent findings. Harv Rev Psychiatry 1999;7(1):1-28.
44. Stewart DE. Antidepressant drugs during pregnancy and lactation. Int Clin Psychopharmacol 2000;15(Suppl 3):S19-24.
45. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: Weighing the risks. J Clin Psychiatry 1998;59(Suppl 2):18-28.
46. Misri S, Kostaras D, Kostaras X. The use of selective serotonin reuptake inhibitors during pregnancy and lactation: Current knowledge. Can J Psychiatry 2000;45(3):285-7.
47. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156(7):1000-6.
48. Remick RA. Long term pharmacological treatment of mood disorders. In: Ancill R, Lader M, Tindall B, editors. Pharmacological Management of Chronic Psychiatric Disorders. London: Balliere Tindall; 1995. p. 553-63.
49. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998;12:305-13.
50. Potter WZ, Rudorfer MV. Electroconvulsive therapy - A modern medical procedure [editorial]. N Engl J Med 1993;328:882-3.
51. Kraus RP, Chandarana P. Say, are you psychiatrists still using ECT? CMAJ 1997;157:1375-7.
52. Sackeim HA, Luber B, Katzman GP, Moeller JR, Prudic J, Devanand DP, et al. The effects of electroconvulsive therapy on quantitative electroencephalograms. Relationship to clinical outcome. Arch Gen Psychiatry 1996;53:814-24.
53. Lam RW, Levitt AJ. Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder. Vancouver: Clinical & Academic Publishing; 1999.
54. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression - An overview and meta-analysis of randomised clinical trials. BMJ 1996;313:253-8.
55. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, et al. Effectiveness of St John's wort in major depression: A randomized controlled trial. JAMA 2001;285:1978-86.
56. Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: Systematic review and meta-regression analysis of randomised controlled trials. BMJ 2001;322:763-7.
57. Wirz-Justice A, van den Hoofdakker RH. Sleep deprivation in depression: What do we know, where do we go? Biol Psychiatry 1999;46:445-53.
58. Bridges PK, Bartlett JR, Hale AS, Poynton AM, Malizia AL, Hodgkiss AD. Psychosurgery: Stereotactic subcaudate tractomy. An indispensable treatment. Br J Psychiatry 1994;165:599-611.
59. George MS, Sackeim HA, Marangell LB, Husain MM, Nahas Z, Lisanby SH, et al. Vagus nerve stimulation. A potential therapy for resistant depression? Psychiatr Clin North Am 2000;23:757-83.
60. Hasey G, Joffe R, Ivanski C. Managing neuropsychiatic disease with transcranial magnetic stimulation. CMAJ 2000;162:78-80.
61. Keller MB, McCullough JP, Klein DN, Arrow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70.
62. Ravindran AV, Anisman H, Merali Z, Charbonneau Y, Telner J, Bialik RJ, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. Am J Psychiatry 1999;156:1608-17.
63. Frank E, Grochocinski VJ, Spanier CA, Buysse DJ, Cherry CR, Houck PR, et al. Interpersonal psychotherapy and antidepressant medication: Evaluation of a sequential treatment strategy in women with recurrent major depression. J Clin Psychiatry 2000;61:51-7.
64. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York: Guilford Press; 1979.
65. Greenberg D, Padesky CA. Mind Over Mood. New York: Guilford Press; 1995.
66. Weissman MM, Markowitz JC, Klerman GL. A comprehensive guide to interpersonal psychotherapy. New York: Basic Books; 2000.
67. Segal ZV, Kennedy SH, Cohen NL, and the CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. V. Combining psychotherapy and pharmacotherapy. Can J Psychiatry 2001;46(Suppl 1):59S-62S.